The active component of Eltrombopag 25 mg is Eltrombopag Olamine, a thrombopoietin receptor agonist that is mainly utilized to increase blood platelet synthesis. It is recommended for individuals with severe aplastic anemia, hepatitis C-associated thrombocytopenia, and persistent immune thrombocytopenia (ITP), particularly when alternative therapies have not produced satisfactory outcomes.

In order to lower the risk of bleeding issues and improve the quality of life for patients with platelet abnormalities, this drug is designed to enhance the body’s natural platelet creation process.

Mechanism of Action

The active ingredient in Eltrombopag 25 mg, eltrombopag, attaches itself to hematopoietic cells in the bone marrow and activates the thrombopoietin (TPO) receptor. Megakaryocytes, the progenitors of platelets, are stimulated to proliferate and differentiate by this activation, which imitates the natural hormone thrombopoietin. Platelet counts rise as a result, enhancing hemostatic performance and lowering the risk of bleeding episodes.

Eltrombopag 25 mg functions internally, improving the body’s capacity to generate and sustain sufficient platelet levels over time, in contrast to external platelet infusions.

Indications

Eltrombopag 25 mg Olamine) is indicated for use in the following medical conditions:

Chronic Immune Thrombocytopenia (ITP): In adults and children aged 1 year and older with ITP for at least six months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Thrombocytopenia in Hepatitis C Patients: In adults with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy.

Severe Aplastic Anemia (SAA): In patients who are either unresponsive to immunosuppressive therapy or not candidates for hematopoietic stem cell transplantation.

Dosage and Administration

The recommended dose of Eltrombopag 25 mg is individualized based on the patient’s platelet count and clinical response. For adults with ITP, the typical starting dose is 25 mg once daily, with adjustments made based on platelet counts. Dosage may differ for patients with hepatic impairment or those taking interacting medications.

Route: Oral

Administration: Taken on an empty stomach (1 hour before or 2 hours after a meal), avoiding calcium-rich foods and mineral supplements during the time of dosing to ensure optimal absorption.

It is essential for patients to follow their healthcare provider’s instructions carefu+

lly and undergo regular monitoring of blood counts to ensure efficacy and minimize risks.

Contraindications

Patients who are known to be hypersensitive to eltrombopag or any of its ingredients should not take 25 mg of Eltrombopag 25 mg. People with a history of thromboembolic events shouldn’t use it unless the possible advantages outweigh the hazards.

Warnings and Precautions

Hepatotoxicity: Regular monitoring of liver function is necessary. If your ALT or AST levels noticeably increase, stop.

Thrombotic Risk: Dosage modifications are necessary because elevated platelet counts can raise the risk of thrombotic events.

Cataracts: Because eltrombopag has been linked in animal studies to the development of cataracts, routine eye exams are advised.

Bone Marrow Fibrosis: Prolonged use may cause alterations in the bone marrow; routine bone marrow tests may be necessary.

Drug Interactions

Eltrombopag may interact with the following:

Antacids and supplements containing polyvalent cations (calcium, iron, magnesium, aluminum), which can reduce drug absorption.

Statins and certain antiviral drugs, which may affect liver enzymes and increase eltrombopag levels.

Patients should inform their healthcare provider of all medications and supplements they are taking to avoid adverse interactions.

Side Effects

Eltrombopag 25 mg side effects frequently include:

Feeling queasy

Having diarrhea

A headache

Weariness

Increased liver enzyme levels

Serious adverse effects could consist of:

Blood clots (pulmonary embolism, deep vein thrombosis)

Toxicology of the liver

Development of cataracts

Keep at room temperature, between 15°C and 30°C.

To keep it dry, keep it in its original container.

Keep out of children’s reach.

Conclusion

A major improvement in the management of diseases associated with chronic thrombocytopenia is provided by Eltrombopag 25 mg. It lowers the danger of bleeding and promotes improved clinical results by increasing the body’s own platelet production. Like all drugs, it must be used under close medical supervision and monitored often to guarantee efficacy and safety.

Order Now At Mdx Pharma bd….

To order from MDX Pharma BD, visit their website at https://mdxpharmabd.com, where you can browse products and place orders online. For inquiries or orders via email, contact emedicarepharma@gmail.com. Alternatively, call (+88) 01929123476. Their address is 29, Abdullahpur, Uttara, Dhaka-1230, Bangladesh.

1. What is the purpose of eltrombopag olamine?
a medication used to treat children and adults with chronic immunological thrombocytopenic purpura who have thrombocytopenia (low blood platelet count) that did not improve with earlier treatments. Additionally, severe aplastic anemia is treated with eltrombopag olamine.

2. What is the purpose of eltrombopag 25 mg?
Eltrombopag is used to treat people with chronic immune thrombocytopenia (ITP), a blood condition characterized by insufficient platelets in the blood. After a splenectomy (splenic removal operation) and other medications (such as immunoglobulin or steroids) have not been effective enough, this medication is taken.

3. What is Eltrombopag Olamine’s equivalent?
12.5 mg film-coated Revolade tablets The amount of eltrombopag olamine in each film-coated tablet is 12.5 mg. 25 mg film-coated tablets of Revolade The amount of eltrombopag olamine in each film-coated tablet is 25 mg.

4. How long does eltrombopag treatment last?
The median duration of eltrombopag medication was 237 days (range 14–1014 days), and the median period from ITP diagnosis was 24 months (range 6–73 months). Eltrombopag may therefore be able to be tapered gradually and eventually stopped in certain patients with chronic ITP.

5. What time of day is ideal for taking eltrombopag?
Typically, it is taken once daily on an empty stomach, either two hours after eating or at least one hour before. Every day, take eltrombopag at roughly the same time. Pay close attention to the instructions on your prescription label, and ask your pharmacist or doctor to clarify any parts you don’t understand.